Conference Coverage

Fungal cultures in bronchiectasis don’t predict outcomes


 

Expert opinion

Several of the experts at the presentation provided an opinion. Some reported that they would continue to order fungal cultures on a routine basis, while others said that they now, on the basis of these data, plan to order cultures only at the first visit or when fungal infection is suspected of exacerbating the disease.

Of this latter group, which seemed to be dominant, Juzar Ali, MD, professor of medicine, Louisiana State University, New Orleans, said that he has not been ordering fungal cultures on every visit. Rather, he has been doing so selectively. Examples include those who are on steroids or those with an unusual pattern of exacerbations.

“The value of these data is that they have now provided some data to support this approach,” Dr. Ali said in an interview. Noting that this is the first large study to address this question in a systematic way, he considers this to be a valuable contribution for approaching a common clinical issue.

Dr. McShane reports no relevant financial relationships. Dr. Ali reports a financial relationship with Insmed.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

New drugs in primary care: Lessons learned from COVID-19
MDedge Infectious Disease
Study of hospitalizations in Canada quantifies benefit of COVID-19 vaccine to reduce death, ICU admissions
MDedge Infectious Disease
The enemy of carcinogenic fumes is my friendly begonia
MDedge Infectious Disease
Antibiotics for acute exacerbation of COPD: It’s still controversial
MDedge Infectious Disease
The evolving pulmonary landscape in HIV
MDedge Infectious Disease
CDC signs off on RSV vaccine for older adults
MDedge Infectious Disease
Comorbid respiratory disease key predictor of NTM-PD
MDedge Infectious Disease
LAMA-LABA surpasses corticosteroid combination as COPD therapy
MDedge Infectious Disease
FDA approves RSV monoclonal antibody for all infants
MDedge Infectious Disease
Pneumococcal vaccine label adds injection-site risk
MDedge Infectious Disease